株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Errant Gene Therapeutics, LLC:製品パイプライン分析

Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 257882
出版日 ページ情報 英文 23 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Errant Gene Therapeutics, LLC:製品パイプライン分析 Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015
出版日: 2015年04月29日 ページ情報: 英文 23 Pages
概要

Errant Gene Therapeutics, LLC は、ルー・ゲーリック病、嚢胞性線維症、ハンチントン病、鎌状赤血球性貧血、地中海貧血などといった致命的な病気の治療薬を開発製造し、提供する製薬会社です。同社はまた、遺伝子のクロマチン構造の化学変調と遺伝子療法という2つの技術を用いたワクチンを開発しています。

当レポートでは、Errant Gene Therapeutics, LLCにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Errant Gene Therapeutics, LLCの基本情報

  • Errant Gene Therapeutics, LLCの概要
  • 主要情報
  • 企業情報

Errant Gene Therapeutics, LLC:R&Dの概要

  • 主な治療範囲

Errant Gene Therapeutics, LLC:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Errant Gene Therapeutics, LLC:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Errant Gene Therapeutics, LLC:薬剤プロファイル

  • Thalagen
  • CG-1521
  • Trichostatin A
  • Gene Therapy for Sickle Cell Anemia
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD

Errant Gene Therapeutics, LLC:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Errant Gene Therapeutics, LLC:休止中のプロジェクト

Errant Gene Therapeutics, LLC:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07024CDB

Summary

Global Markets Direct's, 'Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015', provides an overview of the Errant Gene Therapeutics, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Errant Gene Therapeutics, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Errant Gene Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Errant Gene Therapeutics, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Errant Gene Therapeutics, LLC's pipeline products

Reasons to buy

  • Evaluate Errant Gene Therapeutics, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Errant Gene Therapeutics, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Errant Gene Therapeutics, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Errant Gene Therapeutics, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Errant Gene Therapeutics, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Errant Gene Therapeutics, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Errant Gene Therapeutics, LLC Snapshot
    • Errant Gene Therapeutics, LLC Overview
    • Key Information
    • Key Facts
  • Errant Gene Therapeutics, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Errant Gene Therapeutics, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Errant Gene Therapeutics, LLC - Pipeline Products Glance
    • Errant Gene Therapeutics, LLC - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Errant Gene Therapeutics, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Errant Gene Therapeutics, LLC - Drug Profiles
    • Thalagen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-1521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trichosic
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Sickle Cell Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Errant Gene Therapeutics, LLC - Pipeline Analysis
  • Errant Gene Therapeutics, LLC - Pipeline Products by Target
  • Errant Gene Therapeutics, LLC - Pipeline Products by Route of Administration
  • Errant Gene Therapeutics, LLC - Pipeline Products by Molecule Type
  • Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action
  • Errant Gene Therapeutics, LLC - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Errant Gene Therapeutics, LLC, Key Information
  • Errant Gene Therapeutics, LLC, Key Facts
  • Errant Gene Therapeutics, LLC - Pipeline by Indication, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • Errant Gene Therapeutics, LLC - Phase I, 2015
  • Errant Gene Therapeutics, LLC - Preclinical, 2015
  • Errant Gene Therapeutics, LLC - Discovery, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Target, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Route of Administration, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Molecule Type, 2015
  • Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2015
  • Errant Gene Therapeutics, LLC, Other Locations

List of Figures

  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Indication, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Target, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Molecule Type, 2015
  • Errant Gene Therapeutics, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top